Socorro Asset Management LP Reduces Stock Holdings in Pfizer Inc. $PFE

Socorro Asset Management LP lessened its holdings in Pfizer Inc. (NYSE:PFE) by 17.3% during the first quarter, Holdings Channel.com reports. The firm owned 315,112 shares of the biopharmaceutical company’s stock after selling 66,114 shares during the quarter. Pfizer comprises about 4.0% of Socorro Asset Management LP’s portfolio, making the stock its 6th largest holding. Socorro Asset Management LP’s holdings in Pfizer were worth $8,848,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the business. Excelsior Advisor Network LLC lifted its holdings in shares of Pfizer by 3.4% during the first quarter. Excelsior Advisor Network LLC now owns 13,888 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 453 shares during the last quarter. Quantinno Capital Management LP grew its stake in shares of Pfizer by 10.4% in the 1st quarter. Quantinno Capital Management LP now owns 1,855,826 shares of the biopharmaceutical company’s stock worth $52,112,000 after buying an additional 175,560 shares during the last quarter. SummitTX Capital L.P. bought a new position in Pfizer during the 1st quarter valued at approximately $807,000. Family Manage LLC raised its stake in Pfizer by 8.7% during the first quarter. Family Manage LLC now owns 15,433 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 1,231 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its holdings in Pfizer by 17.8% in the first quarter. Orbimed Advisors LLC now owns 1,946,500 shares of the biopharmaceutical company’s stock worth $54,658,000 after acquiring an additional 293,600 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $24.68 on Tuesday. The company has a market cap of $140.63 billion, a price-to-earnings ratio of 18.84 and a beta of 0.35. The business’s fifty day simple moving average is $25.10 and its two-hundred day simple moving average is $26.17. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. Guggenheim cut their target price on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Morgan Stanley upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Finally, BMO Capital Markets reduced their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.50.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.